Skip to main content

Advertisement

SpringerLink
Log in

Pediatric Onco-Nephrology: Time to Spread the Word-Part II: Long-Term Kidney Outcomes in Survivors of Childhood Malignancy and Malignancy after Kidney Transplant

  • Educational Review
  • Published:
Pediatric Nephrology Aims and scope Submit manuscript

Abstract

Onco-nephrology is a recent and evolving medical subspecialty devoted to the care of patients with kidney disease and unique kidney-related complications in the context of cancer and its treatments, recognizing that management of kidney disease as well as the cancer itself will improve survival and quality of life. While this area has received much attention in the adult medicine sphere, similar emphasis in the pediatric realm has not yet been realized. As in adults, kidney involvement in children with cancer extends beyond the time of initial diagnosis and treatment. Many interventions, such as chemotherapy, stem cell transplant, radiation, and nephrectomy, have long-term kidney effects, including the development of chronic kidney disease (CKD) with subsequent need for dialysis and/or kidney transplant. Thus, with the improved survival of children with malignancy comes the need for ongoing monitoring of kidney function and early mitigation of kidney-related comorbidities. In addition, children with kidney transplant are at higher risk of developing malignancies than their age-matched peers. Pediatric nephrologists thus need to be aware of issues related to cancer and its treatments as they impact their own patients. These facts emphasize the necessity of pediatric nephrologists and oncologists working closely together in managing these children and highlight the importance of bringing the onco-nephrology field to our growing list of pediatric nephrology subspecialties.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Siegel RL, Miller KD, Jemal A (2018) Cancer statistics, 2018. CA Cancer J Clin 68:7–30

    Article  PubMed  Google Scholar 

  2. Nada A, Jetton JG (2020) Pediatric onco-nephrology: time to spread the word: Part I: early kidney involvement in children with malignancy. Pediatr Nephrol. https://doi.org/10.1007/s00467-020-04800-3

  3. Keaney CM, Springate JE (2005) Cancer and the kidney. Adolesc Med Clin 16:121–148

    Article  PubMed  Google Scholar 

  4. Levey AS, Coresh J, Balk E, Kausz AT, Levin A, Steffes MW et al (2003) National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Ann Intern Med 139:137–147

    Article  PubMed  Google Scholar 

  5. Robison LL, Armstrong GT, Boice JD, Chow EJ, Davies SM, Donaldson SS et al (2009) The Childhood Cancer Survivor Study: a National Cancer Institute-supported resource for outcome and intervention research. J Clin Oncol 27:2308–2318

    Article  PubMed  PubMed Central  Google Scholar 

  6. Gutierrez-Millet V, Nieto J, Praga M, Usera G, Martinez MA, Morales JM (1986) Focal glomerulosclerosis and proteinuria in patients with solitary kidneys. Arch Intern Med 146:705–709

    Article  CAS  PubMed  Google Scholar 

  7. Knijnenburg SL, Jaspers MW, van der Pal HJ, Schouten-van Meeteren AY, Bouts AH, Lieverst JA et al (2012) Renal dysfunction and elevated blood pressure in long-term childhood cancer survivors. Clin J Am Soc Nephrol 7:1416–1427

    Article  PubMed  PubMed Central  Google Scholar 

  8. Interiano RB, Delos Santos N, Huang S, Srivastava DK, Robison LL, Hudson MM et al (2015) Renal function in survivors of nonsyndromic Wilms tumor treated with unilateral radical nephrectomy. Cancer 121:2449–2456

    Article  PubMed  Google Scholar 

  9. de Graaf SS, van Gent H, Reitsma-Bierens WC, van Luyk WH, Dolsma WV, Postma A (1996) Renal function after unilateral nephrectomy for Wilms’ tumour: the influence of radiation therapy. Eur J Cancer 32A:465–469

    Article  PubMed  Google Scholar 

  10. Finklestein JZ, Norkool P, Green DM, Breslow N, D'Angio GJ (1993) Diastolic hypertension in Wilms’ tumor survivors: a late effect of treatment? A report from the National Wilms’ Tumor Study Group. Am J Clin Oncol 16:201–205

    Article  CAS  PubMed  Google Scholar 

  11. http://www.survivorshipguidelines.org/pdf/2018/COG_LTFU_Guidelines_v5.pdf.

  12. Skinner R, Cotterill SJ, Stevens MC (2000) Risk factors for nephrotoxicity after ifosfamide treatment in children: a UKCCSG Late Effects Group study. United Kingdom Children's Cancer Study Group. Br J Cancer 82:1636–1645

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Suarez A, McDowell H, Niaudet P, Comoy E, Flamant F (1991) Long-term follow-up of ifosfamide renal toxicity in children treated for malignant mesenchymal tumors: an International Society of Pediatric Oncology report. J Clin Oncol 9:2177–2182

    Article  CAS  PubMed  Google Scholar 

  14. Berrak SG, Pearson M, Berberoglu S, Ilhan IE, Jaffe N (2005) High-dose ifosfamide in relapsed pediatric osteosarcoma: therapeutic effects and renal toxicity. Pediatr Blood Cancer 44:215–219

    Article  PubMed  Google Scholar 

  15. Ho PT, Zimmerman K, Wexler LH, Blaney S, Jarosinski P, Weaver-McClure L et al (1995) A prospective evaluation of ifosfamide-related nephrotoxicity in children and young adults. Cancer 76:2557–2564

    Article  CAS  PubMed  Google Scholar 

  16. Latcha S, Jaimes EA, Patil S, Glezerman IG, Mehta S, Flombaum CD (2016) Long-term renal outcomes after cisplatin treatment. Clin J Am Soc Nephrol 11:1173–1179

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Brock PR, Koliouskas DE, Barratt TM, Yeomans E, Pritchard J (1991) Partial reversibility of cisplatin nephrotoxicity in children. J Pediatr 118:531–534

    Article  CAS  PubMed  Google Scholar 

  18. McMahon KR, Harel-Sterling M, Pizzi M, Huynh L, Hessey E, Zappitelli M (2018) Long-term renal follow-up of children treated with cisplatin, carboplatin, or ifosfamide: a pilot study. Pediatr Nephrol 33:2311–2320

    Article  PubMed  Google Scholar 

  19. Widemann BC, Balis FM, Kempf-Bielack B, Bielack S, Pratt CB, Ferrari S et al (2004) High-dose methotrexate-induced nephrotoxicity in patients with osteosarcoma. Cancer 100:2222–2232

    Article  CAS  PubMed  Google Scholar 

  20. Gronroos MH, Jahnukainen T, Mottonen M, Perkkio M, Irjala K, Salmi TT (2008) Long-term follow-up of renal function after high-dose methotrexate treatment in children. Pediatr Blood Cancer 51:535–539

    Article  PubMed  Google Scholar 

  21. Van Why SK, Friedman AL, Wei LJ, Hong R (1991) Renal insufficiency after bone marrow transplantation in children. Bone Marrow Transplant 7:383–388

    PubMed  Google Scholar 

  22. Kist-van Holthe JE, van Zwet JM, Brand R, van Weel MH, Vossen JM, van der Heijden AJ (1998) Bone marrow transplantation in children: consequences for renal function shortly after and 1 year post-BMT. Bone Marrow Transplant 22:559–564

    Article  CAS  PubMed  Google Scholar 

  23. Frisk P, Bratteby LE, Carlson K, Lonnerholm G (2002) Renal function after autologous bone marrow transplantation in children: a long-term prospective study. Bone Marrow Transplant 29:129–136

    Article  CAS  PubMed  Google Scholar 

  24. Patzer L, Ringelmann F, Kentouche K, Fuchs D, Zintl F, Brandis M et al (2001) Renal function in long-term survivors of stem cell transplantation in childhood. A prospective trial. Bone Marrow Transplant 27:319–327

    Article  CAS  PubMed  Google Scholar 

  25. Hoffmeister PA, Hingorani SR, Storer BE, Baker KS, Sanders JE (2010) Hypertension in long-term survivors of pediatric hematopoietic cell transplantation. Biol Blood Marrow Transpl 16:515–524

    Article  CAS  Google Scholar 

  26. Abboud I, Peraldi MN, Hingorani S (2012) Chronic kidney diseases in long-term survivors after allogeneic hematopoietic stem cell transplantation: monitoring and management guidelines. Semin Hematol 49:73–82

    Article  PubMed  Google Scholar 

  27. Hingorani S, Gooley T, Pao E, Sandmaier B, McDonald G (2014) Urinary cytokines after HCT: evidence for renal inflammation in the pathogenesis of proteinuria and kidney disease. Bone Marrow Transplant 49:403–409

    Article  CAS  PubMed  Google Scholar 

  28. Cohen EP (2000) Radiation nephropathy after bone marrow transplantation. Kidney Int 58:903–918

    Article  CAS  PubMed  Google Scholar 

  29. Lawton CA, Cohen EP, Barber-Derus SW, Murray KJ, Ash RC, Casper JT et al (1991) Late renal dysfunction in adult survivors of bone marrow transplantation. Cancer 67:2795–2800

    Article  CAS  PubMed  Google Scholar 

  30. Cohen EP, Lawton CA, Moulder JE (1995) Bone marrow transplant nephropathy: radiation nephritis revisited. Nephron 70:217–222

    Article  CAS  PubMed  Google Scholar 

  31. Pettitt AR, Clark RE (1994) Thrombotic microangiopathy following bone marrow transplantation. Bone Marrow Transplant 14:495–504

    CAS  PubMed  Google Scholar 

  32. Juckett M, Perry EH, Daniels BS, Weisdorf DJ (1991) Hemolytic uremic syndrome following bone marrow transplantation. Bone Marrow Transplant 7:405–409

    CAS  PubMed  Google Scholar 

  33. Takatsuka H, Takemoto Y, Okamoto T, Fujimori Y, Tamura S, Wada H et al (1999) Thrombotic microangiopathy following allogeneic bone marrow transplantation. Bone Marrow Transplant 24:303–306

    Article  CAS  PubMed  Google Scholar 

  34. Antignac C, Gubler MC, Leverger G, Broyer M, Habib R (1989) Delayed renal failure with extensive mesangiolysis following bone marrow transplantation. Kidney Int 35:1336–1344

    Article  CAS  PubMed  Google Scholar 

  35. El-Seisi S, Gupta R, Clase CM, Forrest DL, Milandinovic M, Couban S (2003) Renal pathology at autopsy in patients who died after hematopoietic stem cell transplantation. Biol Blood Marrow Transpl 9:683–688

    Article  Google Scholar 

  36. Moulder JE, Fish BL, Cohen EP (1998) Radiation nephropathy is treatable with an angiotensin converting enzyme inhibitor or an angiotensin II type-1 (AT1) receptor antagonist. Radiother Oncol 46:307–315

    Article  CAS  PubMed  Google Scholar 

  37. Kemper MJ, Gungor T, Halter J, Schanz U, Neuhaus TJ (2007) Favorable long-term outcome of nephrotic syndrome after allogeneic hematopoietic stem cell transplantation. Clin Nephrol 67:5–11

    Article  CAS  PubMed  Google Scholar 

  38. Colombo AA, Rusconi C, Esposito C, Bernasconi P, Caldera D, Lazzarino M et al (2006) Nephrotic syndrome after allogeneic hematopoietic stem cell transplantation as a late complication of chronic graft-versus-host disease. Transplantation 81:1087–1092

    Article  PubMed  Google Scholar 

  39. Srinivasan R, Balow JE, Sabnis S, Lundqvist A, Igarashi T, Takahashi Y et al (2005) Nephrotic syndrome: an under-recognised immune-mediated complication of non-myeloablative allogeneic haematopoietic cell transplantation. Br J Haematol 131:74–79

    Article  CAS  PubMed  Google Scholar 

  40. Chien YH, Lin KH, Lee TY, Lu MY, Tsau YK (2000) Nephrotic syndrome in a bone marrow transplant recipient without chronic graft-versus-host disease. J Formos Med Assoc 99:503–506

    CAS  PubMed  Google Scholar 

  41. Hiesse C, Goldschmidt E, Santelli G, Charpentier B, Machover D, Fries D (1988) Membranous nephropathy in a bone marrow transplant recipient. Am J Kidney Dis 11:188–191

    Article  CAS  PubMed  Google Scholar 

  42. Mathieson PW (2003) Immune dysregulation in minimal change nephropathy. Nephrol Dial Transplant 18(Suppl 6):vi26–vi29

    CAS  PubMed  Google Scholar 

  43. Rizzo JD, Wingard JR, Tichelli A, Lee SJ, Van Lint MT, Burns LJ et al (2006) Recommended screening and preventive practices for long-term survivors after hematopoietic cell transplantation: joint recommendations of the European Group for Blood and Marrow Transplantation, the Center for International Blood and Marrow Transplant Research, and the American Society of Blood and Marrow Transplantation. Biol Blood Marrow Transpl 12:138–151

    Article  Google Scholar 

  44. Cassady JR (1995) Clinical radiation nephropathy. Int J Radiat Oncol Biol Phys 31:1249–1256

    Article  CAS  PubMed  Google Scholar 

  45. Baldwin JN, Hagstrom JW (1962) Acute radiation nephritis. Calif Med 97:359–362

    CAS  PubMed  PubMed Central  Google Scholar 

  46. Bolling T, Schuck A, Pape H, Rube C, Meyer FM, Martini C et al (2007) Register for the evaluation of side effects after radiation in childhood and adolescence--first results. Klin Padiatr 219:139–145

    Article  CAS  PubMed  Google Scholar 

  47. Carrie C, Thomas P (2008) The Pediatric Radiation Oncology Society (PROS): why? Int J Radiat Oncol Biol Phys 71:666

    Article  PubMed  Google Scholar 

  48. Ritchey ML, Green DM, Thomas PR, Smith GR, Haase G, Shochat S et al (1996) Renal failure in Wilms’ tumor patients: a report from the National Wilms’ Tumor Study Group. Med Pediatr Oncol 26:75–80

    Article  CAS  PubMed  Google Scholar 

  49. Mitus A, Tefft M, Fellers FX (1969) Long-term follow-up of renal functions of 108 children who underwent nephrectomy for malignant disease. Pediatrics 44:912–921

    Article  CAS  PubMed  Google Scholar 

  50. Krochak RJ, Baker DG (1986) Radiation nephritis. Clinical manifestations and pathophysiologic mechanisms. Urology 27:389–393

    Article  CAS  PubMed  Google Scholar 

  51. Cohen EP, Pais P, Moulder JE (2010) Chronic kidney disease after hematopoietic stem cell transplantation. Semin Nephrol 30:627–634

    Article  PubMed  PubMed Central  Google Scholar 

  52. White DC (1976) The histopathologic basis for functional decrements in late radiation injury in diverse organs. Cancer 37(2 Suppl):1126–1143

    Article  CAS  PubMed  Google Scholar 

  53. Choi KL, Bakris GL (2005) Hypertension treatment guidelines: practical implications. Semin Nephrol 25:198–209

    Article  PubMed  Google Scholar 

  54. Batabyal P, Chapman JR, Wong G, Craig JC, Tong A (2012) Clinical practice guidelines on wait-listing for kidney transplantation: consistent and equitable? Transplantation 94:703–713

    Article  PubMed  Google Scholar 

  55. Chapman JR, Sheil AG, Disney AP (2001) Recurrence of cancer after renal transplantation. Transplant Proc 33:1830–1831

    Article  CAS  PubMed  Google Scholar 

  56. Penn I (1993) The effect of immunosuppression on pre-existing cancers. Transplantation 55:742–747

    Article  CAS  PubMed  Google Scholar 

  57. Engels EA, Pfeiffer RM, Fraumeni JF Jr, Kasiske BL, Israni AK, Snyder JJ et al (2011) Spectrum of cancer risk among US solid organ transplant recipients. JAMA 306:1891–1901

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  58. Collett D, Mumford L, Banner NR, Neuberger J, Watson C (2010) Comparison of the incidence of malignancy in recipients of different types of organ: a UK Registry audit. Am J Transplant 10:1889–1896

    Article  CAS  PubMed  Google Scholar 

  59. Samuel SM, Tonelli MA, Foster BJ, Alexander RT, Nettel-Aguirre A, Soo A et al (2011) Survival in pediatric dialysis and transplant patients. Clin J Am Soc Nephrol 6:1094–1099

    Article  PubMed  PubMed Central  Google Scholar 

  60. Tessari G, Naldi L, Boschiero L, Minetti E, Sandrini S, Nacchia F et al (2013) Incidence of primary and second cancers in renal transplant recipients: a multicenter cohort study. Am J Transplant 13:214–221

    Article  CAS  PubMed  Google Scholar 

  61. Debray D, Baudouin V, Lacaille F, Charbit M, Rivet C, Harambat J et al (2009) De novo malignancy after solid organ transplantation in children. Transplant Proc 41:674–675

    Article  CAS  PubMed  Google Scholar 

  62. Simard JF, Baecklund E, Kinch A, Brattstrom C, Ingvar A, Molin D et al (2011) Pediatric organ transplantation and risk of premalignant and malignant tumors in Sweden. Am J Transplant 11:146–151

    Article  CAS  PubMed  Google Scholar 

  63. Ploos van Amstel S, Vogelzang JL, Starink MV, Jager KJ, Groothoff JW (2015) Long-term risk of cancer in survivors of pediatric ESRD. Clin J Am Soc Nephrol 10:2198–2204

    Article  PubMed  PubMed Central  Google Scholar 

  64. Mucha K, Foroncewicz B, Ziarkiewicz-Wroblewska B, Krawczyk M, Lerut J, Paczek L (2010) Post-transplant lymphoproliferative disorder in view of the new WHO classification: a more rational approach to a protean disease? Nephrol Dial Transplant 25:2089–2098

    Article  PubMed  Google Scholar 

  65. Caillard S, Dharnidharka V, Agodoa L, Bohen E, Abbott K (2005) Posttransplant lymphoproliferative disorders after renal transplantation in the United States in era of modern immunosuppression. Transplantation 80:1233–1243

    Article  CAS  PubMed  Google Scholar 

  66. McDonald RA, Smith JM, Ho M, Lindblad R, Ikle D, Grimm P et al (2008) Incidence of PTLD in pediatric renal transplant recipients receiving basiliximab, calcineurin inhibitor, sirolimus and steroids. Am J Transplant 8:984–989

    Article  CAS  PubMed  Google Scholar 

  67. Haque T, Crawford DH (1998) Role of donor versus recipient type Epstein-Barr virus in post-transplant lymphoproliferative disorders. Springer Semin Immunopathol 20:375–387

    Article  CAS  PubMed  Google Scholar 

  68. Quinlan SC, Pfeiffer RM, Morton LM, Engels EA (2011) Risk factors for early-onset and late-onset post-transplant lymphoproliferative disorder in kidney recipients in the United States. Am J Hematol 86:206–209

    Article  PubMed  PubMed Central  Google Scholar 

  69. Schober T, Framke T, Kreipe H, Schulz TF, Grosshennig A, Hussein K et al (2013) Characteristics of early and late PTLD development in pediatric solid organ transplant recipients. Transplantation 95:240–246

    Article  PubMed  Google Scholar 

  70. Hart A, Smith JM, Skeans MA, Gustafson SK, Stewart DE, Cherikh WS et al (2017) OPTN/SRTR 2015 Annual Data Report: kidney. Am J Transplant 17(Suppl 1):21–116

    Article  PubMed  PubMed Central  Google Scholar 

  71. Dharnidharka VR (2010) Epidemiology of PTLD. In: VRGM D, Webber SA (eds) Post transplant lymphoproliferative disorders, vol 1. Springer-Verlag, Berlin-Heidelberg, pp 17–28

    Chapter  Google Scholar 

  72. van der Molen AJ, Reimer P, Dekkers IA, Bongartz G, Bellin MF, Bertolotto M, Clement O, Heinz-Peer G, Stacul F, Webb JAW, Thomsen HS (2018) Post-contrast acute kidney injury. Part 2: risk stratification, role of hydration and other prophylactic measures, patients taking metformin and chronic dialysis patients : Recommendations for updated ESUR Contrast Medium Safety Committee guideline. Eur Radiol 28:2856–2869

    Article  PubMed  PubMed Central  Google Scholar 

  73. Allen UD, Preiksaitis JK, AST Infectious Diseases Community of Practice (2013) Epstein-Barr virus and posttransplant lymphoproliferative disorder in solid organ transplantation. Am J Transplant 13(Suppl 4):107–120

    Article  CAS  PubMed  Google Scholar 

  74. Al-Mansour Z, Nelson BP, Evens AM (2013) Post-transplant lymphoproliferative disease (PTLD): risk factors, diagnosis, and current treatment strategies. Curr Hematol Malig Rep 8:173–183

    Article  PubMed  PubMed Central  Google Scholar 

  75. Bingler MA, Feingold B, Miller SA, Quivers E, Michaels MG, Green M et al (2008) Chronic high Epstein-Barr viral load state and risk for late-onset posttransplant lymphoproliferative disease/lymphoma in children. Am J Transplant 8:442–445

    Article  CAS  PubMed  Google Scholar 

  76. Dharnidharka VR, Sullivan EK, Stablein DM, Tejani AH, Harmon WE, North American Pediatric Renal Transplant Cooperative Study (2001) Risk factors for posttransplant lymphoproliferative disorder (PTLD) in pediatric kidney transplantation: a report of the North American Pediatric Renal Transplant Cooperative Study (NAPRTCS). Transplantation 71:1065–1068

    Article  CAS  PubMed  Google Scholar 

  77. Mathew T, Kreis H, Friend P (2004) Two-year incidence of malignancy in sirolimus-treated renal transplant recipients: results from five multicenter studies. Clin Transpl 18:446–449

    Article  Google Scholar 

  78. Kahan BD, Yakupoglu YK, Schoenberg L, Knight RJ, Katz SM, Lai D et al (2005) Low incidence of malignancy among sirolimus/cyclosporine-treated renal transplant recipients. Transplantation 80:749–758

    Article  CAS  PubMed  Google Scholar 

  79. Kirk AD, Cherikh WS, Ring M, Burke G, Kaufman D, Knechtle SJ et al (2007) Dissociation of depletional induction and posttransplant lymphoproliferative disease in kidney recipients treated with alemtuzumab. Am J Transplant 7:2619–2625

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  80. Cherikh WS, Kauffman HM, McBride MA, Maghirang J, Swinnen LJ, Hanto DW (2003) Association of the type of induction immunosuppression with posttransplant lymphoproliferative disorder, graft survival, and patient survival after primary kidney transplantation. Transplantation 76:1289–1293

    Article  CAS  PubMed  Google Scholar 

  81. Funch DP, Ko HH, Travasso J, Brady J, Kew CE 2nd, Nalesnik MA et al (2005) Posttransplant lymphoproliferative disorder among renal transplant patients in relation to the use of mycophenolate mofetil. Transplantation 80:1174–1180

    Article  PubMed  Google Scholar 

  82. Perazella MA, Markowitz GS (2008) Bisphosphonate nephrotoxicity. Kidney Int 74:1385–1393

    Article  CAS  PubMed  Google Scholar 

  83. Bustami RT, Ojo AO, Wolfe RA, Merion RM, Bennett WM, McDiarmid SV et al (2004) Immunosuppression and the risk of post-transplant malignancy among cadaveric first kidney transplant recipients. Am J Transplant 4:87–93

    Article  PubMed  Google Scholar 

  84. Opelz G, Henderson R (1993) Incidence of non-Hodgkin lymphoma in kidney and heart transplant recipients. Lancet 342:1514–1516

    Article  CAS  PubMed  Google Scholar 

  85. Grinyo J, Charpentier B, Pestana JM, Vanrenterghem Y, Vincenti F, Reyes-Acevedo R et al (2010) An integrated safety profile analysis of belatacept in kidney transplant recipients. Transplantation 90:1521–1527

    Article  PubMed  Google Scholar 

  86. Kidney Disease: Improving Global Outcomes Transplant Work Group (2009) KDIGO clinical practice guideline for the care of kidney transplant recipients. Am J Transplant 9(Suppl 3):S1–S155

  87. Kasiske BL, Vazquez MA, Harmon WE, Brown RS, Danovitch GM, Gaston RS et al (2000) Recommendations for the outpatient surveillance of renal transplant recipients. American Society of Transplantation. J Am Soc Nephrol 11(Suppl 15):S1–S86

  88. Green M, Reyes J, Webber S, Rowe D (2001) The role of antiviral and immunoglobulin therapy in the prevention of Epstein-Barr virus infection and post-transplant lymphoproliferative disease following solid organ transplantation. Transpl Infect Dis 3:97–103

    Article  CAS  PubMed  Google Scholar 

  89. Hocker B, Bohm S, Fickenscher H, Kusters U, Schnitzler P, Pohl M et al (2012) (Val-)Ganciclovir prophylaxis reduces Epstein-Barr virus primary infection in pediatric renal transplantation. Transpl Int 25:723–731

    Article  PubMed  CAS  Google Scholar 

  90. Funch DP, Walker AM, Schneider G, Ziyadeh NJ, Pescovitz MD (2005) Ganciclovir and acyclovir reduce the risk of post-transplant lymphoproliferative disorder in renal transplant recipients. Am J Transplant 5:2894–2900

    Article  CAS  PubMed  Google Scholar 

  91. Meng Q, Hagemeier SR, Fingeroth JD, Gershburg E, Pagano JS, Kenney SC (2010) The Epstein-Barr virus (EBV)-encoded protein kinase, EBV-PK, but not the thymidine kinase (EBV-TK), is required for ganciclovir and acyclovir inhibition of lytic viral production. J Virol 84:4534–4542

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  92. Green M, Michaels MG, Katz BZ, Burroughs M, Gerber D, Shneider BL et al (2006) CMV-IVIG for prevention of Epstein Barr virus disease and posttransplant lymphoproliferative disease in pediatric liver transplant recipients. Am J Transplant 6:1906–1912

    Article  CAS  PubMed  Google Scholar 

  93. AlDabbagh MA, Gitman MR, Kumar D, Humar A, Rotstein C, Husain S (2017) The role of antiviral prophylaxis for the prevention of Epstein-Barr virus-associated posttransplant lymphoproliferative disease in solid organ transplant recipients: a systematic review. Am J Transplant 17:770–781

    Article  CAS  PubMed  Google Scholar 

  94. Rees L, Tizard EJ, Morgan AJ, Cubitt WD, Finerty S, Oyewole-Eletu TA et al (2009) A phase I trial of Epstein-Barr virus gp350 vaccine for children with chronic kidney disease awaiting transplantation. Transplantation 88:1025–1029

    Article  CAS  PubMed  Google Scholar 

  95. Tsai DE, Hardy CL, Tomaszewski JE, Kotloff RM, Oltoff KM, Somer BG et al (2001) Reduction in immunosuppression as initial therapy for posttransplant lymphoproliferative disorder: analysis of prognostic variables and long-term follow-up of 42 adult patients. Transplantation 71:1076–1088

    Article  CAS  PubMed  Google Scholar 

  96. Reshef R, Vardhanabhuti S, Luskin MR, Heitjan DF, Hadjiliadis D, Goral S et al (2011) Reduction of immunosuppression as initial therapy for posttransplantation lymphoproliferative disorder (bigstar). Am J Transplant 11:336–347

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  97. Dharnidharka VR, Martz KL, Stablein DM, Benfield MR (2011) Improved survival with recent post-transplant lymphoproliferative disorder (PTLD) in children with kidney transplants. Am J Transplant 11:751–758

    Article  CAS  PubMed  Google Scholar 

  98. Choquet S, Trappe R, Leblond V, Jager U, Davi F, Oertel S (2007) CHOP-21 for the treatment of post-transplant lymphoproliferative disorders (PTLD) following solid organ transplantation. Haematologica 92:273–274

    Article  PubMed  Google Scholar 

  99. Gross TG, Bucuvalas JC, Park JR, Greiner TC, Hinrich SH, Kaufman SS et al (2005) Low-dose chemotherapy for Epstein-Barr virus-positive post-transplantation lymphoproliferative disease in children after solid organ transplantation. J Clin Oncol 23:6481–6488

    Article  CAS  PubMed  Google Scholar 

  100. Gross TG, Orjuela MA, Perkins SL, Park JR, Lynch JC, Cairo MS et al (2012) Low-dose chemotherapy and rituximab for posttransplant lymphoproliferative disease (PTLD): a Children’s Oncology Group Report. Am J Transplant 12:3069–3075

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  101. Manez R, Breinig MK, Linden P, Kusne S, Torre-Cisneros J, Wilson J et al (1994) Factors associated with the development of post-transplant lymphoproliferative disease (PTLD) in Epstein-Barr virus (EBV)-seronegative adult liver transplant recipients. Transpl Int 7(Suppl 1):S235–S237

    Article  PubMed  Google Scholar 

  102. Penn I (1986) Cancers of the anogenital region in renal transplant recipients. Analysis of 65 cases. Cancer 58:611–616

    Article  CAS  PubMed  Google Scholar 

  103. Arends MJ, Benton EC, McLaren KM, Stark LA, Hunter JA, Bird CC (1997) Renal allograft recipients with high susceptibility to cutaneous malignancy have an increased prevalence of human papillomavirus DNA in skin tumours and a greater risk of anogenital malignancy. Br J Cancer 75:722–728

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  104. Hartevelt MM, Bavinck JN, Kootte AM, Vermeer BJ, Vandenbroucke JP (1990) Incidence of skin cancer after renal transplantation in The Netherlands. Transplantation 49:506–509

    Article  CAS  PubMed  Google Scholar 

  105. Mullen DL, Silverberg SG, Penn I, Hammond WS (1976) Squamous cell carcinoma of the skin and lip in renal homograft recipients. Cancer 37:729–734

    Article  CAS  PubMed  Google Scholar 

  106. Blohme I, Brynger H (1985) Malignant disease in renal transplant patients. Transplantation 39:23–25

    CAS  PubMed  Google Scholar 

  107. Penn I (1993) Neoplastic complications of transplantation. Semin Respir Infect 8:233–239

    CAS  PubMed  Google Scholar 

  108. Smith JM, Martz K, McDonald RA, Harmon WE (2013) Solid tumors following kidney transplantation in children. Pediatr Transplant 17:726–730

    Article  PubMed  Google Scholar 

  109. Penn I (1995) Primary kidney tumors before and after renal transplantation. Transplantation 59:480–485

  110. Williams JC, Merguerian PA, Schned AR, Morrison PM (1995) Acquired renal cystic disease and renal cell carcinoma in an allograft kidney. J Urol 153:395–396

    Article  CAS  PubMed  Google Scholar 

  111. Baker R, Jardine A, Andrews P (2011) Renal Association Clinical Practice Guideline on post-operative care of the kidney transplant recipient. Nephron Clin Pract 118(Suppl 1):c311–c347

    Article  PubMed  Google Scholar 

  112. EBPG, Expert Group on Renal Transplantation (2002) European best practice guidelines for renal transplantation. Section IV: Long-term management of the transplant recipient. IV.6.3. Cancer risk after renal transplantation. Solid organ cancers: prevention and treatment. Nephrol Dial Transplant 17(Suppl 4):32–34-36

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Le Bonheur Children’s Hospital & St. Jude Research Hospital, The University of Tennessee Health Science Center, Memphis, TN, USA

    Arwa Nada

  2. Stead Family Children’s Hospital: The University of Iowa Stead Family Children’s Hospital, Iowa City, IA, USA

    Jennifer G Jetton

Authors
  1. Arwa Nada
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jennifer G Jetton
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Arwa Nada.

Additional information

Answers:

1. c; 2. d; 3. d; 4. b

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Nada, A., Jetton, J.G. Pediatric Onco-Nephrology: Time to Spread the Word-Part II: Long-Term Kidney Outcomes in Survivors of Childhood Malignancy and Malignancy after Kidney Transplant. Pediatr Nephrol 37, 1285–1300 (2022). https://doi.org/10.1007/s00467-021-05172-y

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00467-021-05172-y

Keywords

Search

Navigation